Cancer care insights: hypoxia in the tumor microenvironment, a biomarker, barrier, or breakthrough?

Abstract

A characteristic of the tumor microenvironment (TME), hypoxia has two functions in the biology of cancer. From one perspective, oxygen deprivation causes metabolic reprogramming, interferes with normal immune surveillance, and increases resistance to treatment. Conversely, hypoxia-inducible pathways have changed the way precision oncology is approached by showing promise as biomarkers and therapeutic targets. Novel approaches for taking advantage of this hostile niche are being revealed by developments in imaging technologies, nanomedicine, and hypoxia-activated prodrugs (HAP). Nevertheless, dynamic oxygen fluctuations and tumor heterogeneity continue to pose a challenge to clinical translation. This editorial discusses whether hypoxia serves primarily as a treatment barrier, a prognostic biomarker, or an intriguing novel therapeutic approach for cancer.

Abbreviations: HAP: Hypoxia-Activated Prodrugs; PKR: Protein Kinase R; TME: Tumor Microenvironment  

Keywords: Hypoxia; Tumor; Microenvironment; Prognostic Biomarkers; Immunotherapy; Hypoxia-Inducible Factor 1; alpha (HIF-1α)

Citation: Asghar N. Zafar K. Cancer care insights: hypoxia in the tumor microenvironment, a biomarker, barrier, or breakthrough? Anaesth. pain intensive care 2026;30(6):659-660. DOI: 10.35975/apic.v30i6.3258

Received: May 09, 2026; Accepted: June 01, 2026